Cover Image

The neural crest-associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Targeted therapy has been established as a therapeutic option for the treatment of metastatic melanoma. Despite initially being very efficient, many tumors develop resistance to targeted therapy, leading to its failure. We previously demonstrated that the neural crest (NC)-associated gene ERRFI1 is...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang, Nina (Author) , Sun, Qian (Author) , Novak, Daniel (Author) , Zhu, Lei (Author) , Poelchen, Juliane (Author) , Steinfass, Tamara (Author) , Wang, Yiman (Author) , Umansky, Viktor (Author) , Utikal, Jochen (Author)
Format: Article (Journal)
Language:English
Published: 2025
In: Molecular oncology
Year: 2025, Pages: 1-17
ISSN:1878-0261
DOI:10.1002/1878-0261.70137
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/1878-0261.70137
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.70137
Get full text
Author Notes:Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky and Jochen Utikal
Description
Summary:Targeted therapy has been established as a therapeutic option for the treatment of metastatic melanoma. Despite initially being very efficient, many tumors develop resistance to targeted therapy, leading to its failure. We previously demonstrated that the neural crest (NC)-associated gene ERRFI1 is highly expressed in metastatic melanoma and correlates with a bad prognosis. Here, we show that the expression of ERRFI1 was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers, such as MITF and TYR. Downregulation of ERRFI1 with the help of siRNA increased the susceptibility of melanoma cells toward BRAF inhibition (BRAFi) and resensitized BRAFi-resistant melanoma cells to BRAFi. Mass spectrometry-based proteomic analysis revealed that ERRFI1 silencing diminished the activation of the mitogen-activated protein kinase (MAPK) and AKT signaling pathways, which usually contribute to drug resistance. Furthermore, we show that miR-200c targeted the 3′UTR of ERRFI1 and reduced its expression, resulting in the resensitization of BRAFi-resistant melanoma cells to BRAFi. Our study results suggest that ERRFI1 could be a potential therapeutic target for the treatment of metastatic melanoma.
Item Description:Erstmals veröffentlicht: 3. Oktober 2025
Gesehen am 27.11.2025
Physical Description:Online Resource
ISSN:1878-0261
DOI:10.1002/1878-0261.70137

Similar Items